Loading...
01/11 08:27
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: strong pipeline developments with FDA fast track designation and cash runway extension are positives, but declining revenue and a net loss are negatives. The Q&A reveals cautious optimism about CF and OTC programs, yet management's lack of clarity on competitor impact and data release timing raises uncertainties. These factors, combined with no new partnerships or shareholder return changes, suggest a neutral stock movement prediction.
Revenue for Q2 2025 $28 million, a decrease of $22 million year-over-year. The decline was primarily driven by lower revenues from the CSL collaboration reflecting lower supply agreement activity and amortization of the upfront payment as CoStave progresses toward global commercialization.
Revenue for H1 2025 $58 million, a decrease of $30 million year-over-year. The decline was primarily driven by lower revenues from the CSL collaboration reflecting lower supply agreement activity and amortization of the upfront payment as CoStave progresses toward global commercialization.
Total Operating Expenses for Q2 2025 $40 million, a decrease from $71 million year-over-year. The reduction was due to lower manufacturing costs for COVID, Flu, and Cystic Fibrosis programs, reduced clinical trial expenses for COVID and OTC, and lower payroll and employee benefits.
Total Operating Expenses for H1 2025 $86 million, a decrease from $139 million year-over-year. The reduction was due to lower manufacturing and clinical costs for the CoStave program, lower payroll and benefit expenses, and reduced facilities and equipment costs, partially offset by higher clinical expenses for the Cystic Fibrosis programs.
Research and Development Expenses for Q2 2025 $29.6 million, a decrease from $58.7 million year-over-year. The decrease was primarily driven by lower manufacturing costs for COVID, Flu, and Cystic Fibrosis programs, reduced clinical trial expenses for COVID and OTC, and lower payroll and employee benefits, partially offset by higher clinical costs for the CF program.
Research and Development Expenses for H1 2025 $64.5 million, a decrease from $112.2 million year-over-year. The decrease was primarily driven by lower manufacturing and clinical costs for the CoStave program, lower payroll and benefit expenses, and reduced facilities and equipment costs, partially offset by higher clinical expenses for the Cystic Fibrosis programs.
General and Administrative Expenses for Q2 2025 $10.3 million, a decrease from $12.3 million year-over-year. The decrease was primarily due to reduced share-based compensation expense as well as reduced headcount and employee benefits.
General and Administrative Expenses for H1 2025 $21.7 million, a decrease from $27.2 million year-over-year. The decrease was primarily due to reduced share-based compensation expense as well as reduced headcount and employee benefits.
Net Loss for Q2 2025 $9.2 million or $0.34 per diluted share, compared with a net loss of $17.2 million or $0.64 per diluted share year-over-year. The improvement was due to reduced operating expenses.
Cash, Cash Equivalents, and Restricted Cash as of June 30, 2025 $253.4 million, compared to $293.9 million as of December 31, 2024. The decrease reflects operational expenses and resource reallocation to the Cystic Fibrosis and OTC programs.
ARCT-032: Advancing enrollment in Phase II trial for Cystic Fibrosis (CF) with daily inhaled treatments over 28 days. Completed enrollment and dosing of 5-mg cohort; progressing to 10-mg cohort. Interim data expected in September 2025. Phase III initiation planned for 2026.
ARCT-810: Positive interim data from Phase II studies for Ornithine Transcarbamylase (OTC) deficiency. Observed decreases in glutamine levels and stable ammonia levels. Preparing for Phase III trial design discussions with FDA in 2026.
CoStave (COVID-19 vaccine): Marketing authorization application filed in the UK; approval expected next month. NDA applications filed in Japan; approvals anticipated this fall. U.S. BLA filing on track for September 2025, with approval decision in 2026.
ARCT-2138: Phase I study for seasonal flu vaccine showed immunogenicity against all 4 influenza strains and no major safety concerns. Demonstrated potential for immune response in young and older adults.
ARCT-2304: Phase I trial for pandemic A/H5N1 influenza virus (bird flu) completed recruitment. FDA Fast Track designation received. Results expected later this year.
COVID-19 vaccine (CoStave): Progressing toward global commercialization with regulatory filings in the UK, Japan, and the U.S.
Restructuring Plan: Streamlined operations to focus on CF and OTC programs, extending cash runway into 2028. Significant reduction in operating expenses year-over-year.
Financial Performance: Revenue for Q2 2025 was $28M, down $22M from Q2 2024. Operating expenses reduced to $40M from $71M in Q2 2024. Net loss reduced to $9.2M from $17.2M in Q2 2024.
Pipeline Focus: Reallocated resources to prioritize CF and OTC programs, aligning with long-term strategic goals.
Regulatory and Clinical Trial Risks: The company anticipates meetings with the FDA and other regulatory agencies in 2026 to discuss Phase II data and plans for pivotal trials for ARCT-032 and ARCT-810. Regulatory approval timelines and outcomes are uncertain and could delay or impact the progression to Phase III trials.
Financial Risks: Revenue for Q2 2025 decreased by $22 million compared to the same period in 2024, primarily due to lower revenues from the CSL collaboration. This decline in revenue could impact the company's financial stability and ability to fund ongoing and future programs.
Operational Risks: The company is undergoing a restructuring plan and consolidating operations, which, while extending the cash runway into 2028, could pose risks related to operational efficiency and employee morale.
Market and Commercialization Risks: The transition of the CoStave program from development to commercialization has led to reduced revenues and lower manufacturing costs. The success of commercialization efforts remains uncertain and could impact future revenue streams.
Pipeline Development Risks: The ARCT-032 and ARCT-810 programs are still in early to mid-stage clinical trials. Any adverse safety or efficacy data could delay or halt development. Additionally, the success of these programs is critical as the company has streamlined its pipeline to focus on these areas.
ARCT-032 Program for Cystic Fibrosis: The company expects to provide Phase II interim data from the first 9 enrolled participants in September 2025. Completion of enrollment for the study is planned by year-end 2025. Meetings with the FDA and regulatory agencies are anticipated in the first half of 2026 to discuss Phase II data and plans for pivotal trials, including adolescent and pediatric participants, with Phase III initiation expected in 2026.
ARCT-810 Program for OTC Deficiency: The company is preparing for meetings with the U.S. FDA and other regulatory agencies to discuss the clinical significance of observed biomarker changes in relation to the design of the Phase III pivotal trial in pediatric studies. Phase III biomarker and trial design alignment with the FDA and other regulatory agencies is expected in the first half of 2026.
CoStave COVID-19 Vaccine: A marketing authorization application to the United Kingdom's MHRA was filed by CSL, with approval expected in September 2025. NDA applications were filed in Japan with anticipated approvals in fall 2025. A U.S. BLA filing to the FDA remains on track for September 2025, with an approval decision expected in 2026.
ARCT-2138 Seasonal Flu Vaccine: Results from a Phase I study demonstrated immunogenicity against all 4 influenza strains and tolerability at tested dose levels. No major safety concerns were raised. The study showed potential for inducing an immune response in both young and older adults.
ARCT-2304 Pandemic A/H5N1 Influenza Vaccine: The company received U.S. FDA Fast Track designation for ARCT-2304. Results from an ongoing Phase I study are expected later in 2025.
The selected topic was not discussed during the call.
The earnings call summary and Q&A reveal mixed signals. While there are positive developments in product pipelines and regulatory progress, management's lack of specific guidance on revenue and clinical endpoints creates uncertainty. The Q&A highlighted potential for growth but also pointed to uncertainties in clinical trial outcomes and commercial revenues. No major catalysts like new partnerships or strong financial metrics were announced, leading to a neutral sentiment overall.
The earnings call presents a mixed picture: strong pipeline developments with FDA fast track designation and cash runway extension are positives, but declining revenue and a net loss are negatives. The Q&A reveals cautious optimism about CF and OTC programs, yet management's lack of clarity on competitor impact and data release timing raises uncertainties. These factors, combined with no new partnerships or shareholder return changes, suggest a neutral stock movement prediction.
The earnings call reveals a decline in revenue and increased net loss, alongside an extended cash runway due to cost reductions and facility consolidation. The Q&A session highlights uncertainties, with management avoiding clear answers on key milestones and guidance. Despite a decrease in expenses, the lack of anticipated revenue milestones until 2028 and unclear regulatory feedback contribute to a negative sentiment. While some operational efficiencies were achieved, the overall financial outlook and management's vague responses suggest a negative stock price movement in the short term.
The earnings call reveals several negative financial indicators: a significant revenue drop, increased operating expenses, and a larger net loss. Despite some positive developments like the KOSTAIVE launch and strategic partnerships, the financial health and guidance issues weigh heavily. The Q&A section shows management's reluctance to provide clear guidance, adding uncertainty. These factors, along with a lack of strong positive catalysts, suggest a negative sentiment. Without market cap data, we assume a moderate negative reaction in stock price, likely between -2% and -8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
